Chapter.14 The Myelodysplastic Syndromes Exam Prep 3e

Chapter 14. The Myelodysplastic Syndromes

Multiple Choice

1. The most common hematological malignancy in the adult population is:

A. Acute leukemia

B. Multiple myeloma

C. Myelodysplastic syndrome

D. Chronic leukemias

L.O. 14.1

2. Which of the following bone marrow blast percentages will be consistent with the FAB classification of refractory anemia with excess of blasts (RAEB)?

A. 5% to 20%

B. 20% to 30%

C. Greater than 30%

D. Less than 5%

L.O. 14.3 & 14.4

3. All of the following are features of the myelodysplastic syndromes except:

A. Anemia

B. Organomegaly

C. Dysplasia

D. Hypercellular marrow

L.O. 14.1

4. The morphological classification of anemia in the myelodysplastic syndromes is:

A. Normocytic, normochromic

B. Microcytic, hypochromic

C. Macrocytic, normochromic

D. Microcytic, normochromic

L.O. 14.1 & 14.3

5. The most effective means of treating iron overload in the myelodysplastic syndromes is:

A. Therapeutic phlebotomy

B. Limiting iron-containing foods

C. Iron chelation therapy

D. Fasting

L.O. 14.6

6. The blast count in most individuals with MDS is less than:

A. 10%

B. 40%

C. 5%

D. 20%

L.O. 14.3

7. Reticulocytopenia is a feature of MDS. Which one of the following is the mechanism behind this process?

A. Heavy tumor burden

B. Marrow aplasia

C. Ineffective erythropoiesis

D. Toxic effects

L.O. 14.1 & 14.3

8. One of the key white cell features in MDS is:

A. Hypersegmented neutrophils

B. Auer rods

C. Döhle bodies

D. Pseudo–Pelger-Huët 

L.O. 14.3

9. Which of the following chromosome disorders in MDS has a poor predictive influence?

A. Chromosome 7 disorder

B. Trisomy 12

C. Trisomy 13

D. 17q deletion

L.O. 14.5

10. All of the following are dysplastic changes of platelets frequently seen in MDS except:

A. Abnormal granulation

B. Micromega karyocytes

C. Giant platelets

D. Platelet satellitism

L.O. 14.3

11. Typically, patients with MDS will exhibit partial or complete absence of:

A. Chromosomes 5 and 7

B. Chromosomes 8 and 12

C. The Y chromosome

D. Dysplasia

L.O. 14.2

12. Refractory anemia is an anemia that:

A. Has more than 5% blasts in the peripheral blood

B. Is resistant to treatment

C. Will usually demonstrate a hypoplastic bone marrow

D. Demonstrates a 17q deletion routinely

L.O. 14.1

NARRBEGIN:

NARREND

13. The cell at the tip of the pointer is:

A. A basophil

B. A malignant cell

C. A hypogranular neutrophil

D. Not a cell; it’s an artifact

NAR: Figure 14-2

L.O. 14.3

NARRBEGIN:

NARREND

14. The cell at the tip of the pointer is a:

A. Hairy cell

B. Basket cell

C. Degenerating lymphocyte

D. Giant platelet

NAR: Figure 14-4

L.O. 14.3

NARRBEGIN:

NARREND

15. The correct name for the cell at the end of the pointer is a:

A. Ringed sideroblast

B. Reticulocyte

C. Giant platelet

D. Siderocyte

NAR: Figure 14-1

L.O. 14.3

16. All of the following are associated with the development of the MDSs except:

A. Alkylating therapy

B. Benzene exposure

C. Alcoholism

D. Radiation

L.O. 14.2

17. The bone marrow and peripheral smear of a patient with an MDS will show dysplastic changes in _____ over time.

A. white blood cells

B. red blood cells

C. platelets

D. All of the above

L.O. 14.3

True/False

18. Deleted 5q MDS is primarily seen in male patients.

L.O. 14.5

19. A major concern for the management of patients with MDSs is iron overload.

L.O. 14.6

20. A large percentage of the MDSs end in an acute leukemia.

L.O. 14.6